Aegis Therapeutics is a drug-delivery and drug-formulation technologies company commercializing its patented drug delivery and protein stabilization technologies through product specific licenses to leading pharmaceutical and biopharmaceutical companies.

Aegis News

Aegis’ Protek® Excipients Provide A Superior Alternative To Polysorbates In Preventing Protein Aggregation And Unwanted Oxidative Damage And Immunogenicity

SAN DIEGO, CA March 23, 2016 — Biotherapeutics incorporating alkylglucosides rather than polysorbates are likely to achieve substantial commercial benefits and a strong and differentiable market franchise for innovator biotherapeutics and biosimilars. Aggregation-induced neutralizing antibodies and anaphylactic reactions sometimes associated with polysorbates are serious and growing concerns of both the FDA and the European Medicines […]

Aegis Awarded 8th Patent for Fast Acting Migraine Nasal Spray Treatment

Aegis’ Intravail® formulation of sumatriptan achieves therapeutic drug levels in approximately 2 to 3 minutes SAN DIEGO, CA March 17, 2016/Marketwire — Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 9,283,280, its eighth patent, third in the US, providing fast acting formulations for triptans, a class of drugs that are […]

Aegis Awarded Russian Patent for Non-Invasive Delivery of Triptan Anti-Migraine Drugs

SAN DIEGO, CA  Sept. 1, 2015/MarketWire — Aegis Therapeutics LLC announced today that it has been awarded its first Russian patent providing expanded coverage for non-invasive delivery of triptan anti-migraine drugs via a simple metered nasal spray. Newly issued Russian Patent No. 2554814, titled: “Compositions for drug administration”, covers fast acting drug formulations utilizing Aegis’ […]

Aegis Therapeutics Awarded Third Patent for Metered Nasal Spray Parathyroid Hormone (PTH) Peptide Drug Formulations

SAN DIEGO, CA  Aug 27, 2015/MarketWire — Aegis Therapeutics LLC announced today that it has been awarded US Patent No. 9,114,069 titled “Antibacterial Compositions for Drug Administration” providing non-toxic formulations of parathyroid hormone and related analogs, including teriparatide (PTH 1-34), suitable for injectable or metered nasal spray administration having intrinsic antimicrobial activity.  The patent formulations […]

Aegis Awarded Chinese and Japanese Patents for Non- Invasive Delivery of Triptan Anti-Migraine Drugs

SAN DIEGO, CA  Aug 11, 2015/MarketWire — Aegis Therapeutics LLC announced today that it has been awarded foreign patents providing expanded coverage for non-invasive delivery of triptan anti-migraine drugs via a simple metered nasal spray. Newly issued Chinese Patent No. ZL200980157305.0 and Japanese Patent No. 5752048, both titled: “Compositions for drug administration”, cover fast acting […]

Dauntless Pharmaceuticals and Aegis Therapeutics Announce Licensing Agreement

SAN DIEGO, July 21, 2015 /PRNewswire/ — Dauntless Pharmaceuticals, Inc. (Dauntless), a biopharmaceutical company focused on the development of specialty drugs and Aegis Therapeutics, LLC (Aegis) today announced a licensing agreement providing Dauntless’ access to Aegis’ Intravail® drug delivery technology for an undisclosed oncology application and an option for three additional drugs. Financial terms were not disclosed. […]

Aegis Awarded U.S. Patent No. 8,927,497 for Non- Invasive Delivery of Anti-Seizure Drugs

SAN DIEGO, CA Feb 18, 2015/MarketWire — Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,927,497 providing broad coverage for non-invasive delivery of anti-seizure drugs via a simple metered nasal spray. The rapidly acting formulations utilize Aegis’ patented Intravail® transmucosal absorption enhancer technology. Aegis now has twenty-one issued patents related […]

Aegis Awarded 2nd Patent for Monoclonal Antibody Formulations that Avoid Oxidative Damage Due to Polysorbate Surfactants

SAN DIEGO, CA October 7, 2014/MarketWire– Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,846,044, dramatically broadening its patent franchise to cover all useful alkylsaccharides for stabilizing any or all monoclonal antibody biotherapeutics. The Aegis ProTek® excipients provide reduced immunogenicity while avoiding the oxidative damage caused by contaminating peroxides and […]

First Non-Injectable GLP-1 Analog for Type-2 Diabetes

Aegis Offers Exclusive License for Patented Exenatide Metered Nasal Spray    San Diego, CA – August 5, 2014 – Aegis announced today that it is offering an exclusive license to develop, commercialize, and sell its patented non-invasive exenatide metered nasal spray  diabetes drug. Exenatide is a 39-amino acid synthetic peptide GLP-1 analog highly effective in […]